In one paragraphArticle in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
28 authors.
Joseph Abi JaoudeDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2283-4765 Alexandria LauDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1900-6982 Yinyin YuanDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8556-4707 Noah S MeimounDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0007-2061-1633 Brian DeDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3468-3359 Kaiping LiaoDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0007-5908-1668 Ramez KouzyDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1521-0495 Humberto R Nieves-JimenezDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1765-2035 Falk PoenischDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0390-6145 Peter A BalterDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4806-8920 Kristy K BrockDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9364-5040 Gabriel O SawakuchiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5560-0650 Jean-Nicolas VautheyDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4921-5427 Ching-Wei D TzengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6035-7288 Diana ShamsutdinovaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1057-1731 Alexander J LazarDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6395-4499 Deyali ChatterjeeDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-3322-1163 Emma B HollidayDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4362-461X Grace L SmithDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3171-2911 Bruce D MinskyDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8434-7930 Prajnan DasDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8253-4190 Albert C KoongDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9824-1643 Sunyoung S LeeDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5954-5991 Hop S Tran CaoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8612-8272 Milind JavleDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9158-0941 Lawrence KwongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8370-1432 Eugene J KoayDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7675-3461 Ethan B LudmirDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5472-5344 Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MNational Cancer Institute (NCI) NIH grant P30 CA016672NCI NIH HHS P30 CA016672
6 · The paper itselfAbstract
purposeAblative radiotherapy (RT) improves clinical outcomes in patients with unresectable intrahepatic cholangiocarcinoma (ICC). Applicability to "supermassive" ICC remains uncertain given smaller tumor diameters in previous studies. We hypothesize that supermassive ICCs are not mutationally or histopathologically different from nonsupermassive ICCs and so would respond favorably to ablative RT. EXPERIMENTAL
designThis is a retrospective study of patients with supermassive ICC treated at the University of Texas MD Anderson Cancer Center (MDACC) and the National Cancer Database (NCDB). Patients treated at MDACC with unresectable ICC, ≥10 cm in diameter, treated with ablative RT or chemotherapy alone were included. Among NCDB patients, patients treated with chemotherapy alone were included. We analyzed overall survival (OS), tumor-related liver failure (TRLF), and treatment toxicity. We further analyzed mutational status and histopathology in supermassive and nonsupermassive ICC tumors.
resultsWe identified 63 patients treated at MDACC. Patients treated with RT showed improved OS compared with patients treated with chemotherapy alone (median OS: 28.7 vs. 11.9 months; adjusted HR = 0.4; P = 0.02). Patients treated with chemotherapy alone had a higher rate of TRLF compared with those who received RT (47.1% vs. 12.1%; P = 0.01). The RT cohort had improved OS compared with a frequency-matched NCDB chemotherapy-only cohort of supermassive ICC (37.6 vs. 8.9 months, P < 0.001). No major differences in mutational status or histopathology were noted between supermassive and nonsupermassive ICC tumors.
conclusionsPatients with supermassive ICC did not show a distinct mutational or histopathologic profile compared with those with nonsupermassive ICC and had promising outcomes with manageable toxicity when treated with ablative RT.
Indexed as
Bile Duct NeoplasmsCholangiocarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationNeoplasm StagingRetrospective StudiesTreatment Outcome
Identifiers
PMID41923341
PMCPMC13078716
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390